Jan 07, 2008 - Neurogen Corporation (Nasdaq: NRGN) announced that it has completed the follow-up component of a Phase 1 multiple ascending dose (MAD) study with NGD-4715, an MCH-1 receptor antagonist being investigated for the treatment of obesity.The initial phase of the MAD study utilized three times per day dosing (tid) for 14 days in healthy obese subjects exposed to a high caloric diet. As previously reported, during this phase moderate induction of the liver enzyme CYP 3A4 occurred, increasing the probability of accelerating metabolism of other drugs administered concomitantly. In addition, during the initial phase of the MAD study, lipid lowering effects were observed... Neurogen's Press Release-
Thursday, January 17, 2008
Neurogen, Results of Multiple Ascending Dose Studies with Experimental Obesity Drug
Jan 07, 2008 - Neurogen Corporation (Nasdaq: NRGN) announced that it has completed the follow-up component of a Phase 1 multiple ascending dose (MAD) study with NGD-4715, an MCH-1 receptor antagonist being investigated for the treatment of obesity.The initial phase of the MAD study utilized three times per day dosing (tid) for 14 days in healthy obese subjects exposed to a high caloric diet. As previously reported, during this phase moderate induction of the liver enzyme CYP 3A4 occurred, increasing the probability of accelerating metabolism of other drugs administered concomitantly. In addition, during the initial phase of the MAD study, lipid lowering effects were observed... Neurogen's Press Release-
Monday, January 14, 2008
Cyberonics , Obesity-Related Patents
Dec. 18, 2008 - Cyberonics, Inc. (Nasdaq: CYBX) announced that effective December 18, 2007, the company has entered into an agreement with 
Ethicon Endo-Surgery granting exclusive rights to the company's patents and patent applications pertaining to vagus nerve stimulation (VNS) for the treatment of obesity and two related co-morbidities, diabetes and hypertension, in overweight patients... Cyberonics' Press Release-
Wednesday, January 9, 2008
EnteroMedics, Nine-Month Clinical Results on Its VBLOC-RF2 Feasibility Study for Obesity Therapy
Jan 08, 2008 - EnteroMedics Inc. (NASDAQ:ETRM), a developer of medical devices using neuroblocking technology to treat obesity and other gastrointestinal disorders, announced interim clinical results for the company's Maestro(TM) RF2 System. The Maestro RF2 System is currently being evaluated in 33 obese patients outside the United States in the VBLOC-RF2 clinical feasibility study of the company's proprietary VBLOC(TM) vagal blocking therapy... EnteroMedics' Press release -